Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Healthtrust
QuintilesIMS
Harvard Business School
Fish and Richardson
US Army
Fuji
Argus Health

Generated: December 16, 2018

DrugPatentWatch Database Preview

SEYSARA Drug Profile

« Back to Dashboard

When do Seysara patents expire, and when can generic versions of Seysara launch?

Seysara is a drug marketed by Allergan Inc and is included in one NDA. There are four patents protecting this drug.

This drug has thirty-eight patent family members in fourteen countries.

The generic ingredient in SEYSARA is sarecycline hydrochloride. One supplier is listed for this compound. Additional details are available on the sarecycline hydrochloride profile page.

Summary for SEYSARA
International Patents:38
US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: 1
DailyMed Link:SEYSARA at DailyMed
Drug patent expirations by year for SEYSARA
Generic Entry Opportunity Date for SEYSARA
Generic Entry Date for SEYSARA*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SEYSARA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Inc SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-001 Oct 1, 2018 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Inc SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-003 Oct 1, 2018 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Inc SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan Inc SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-001 Oct 1, 2018 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Allergan Inc SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Healthtrust
QuintilesIMS
Harvard Business School
Fish and Richardson
US Army
Fuji
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.